News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 27, 2006--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 p.m. EDT on Thursday, May 4, 2006 to discuss the Company's financial results for the quarter ended March 31, 2006 -- the third quarter of ImmunoGen's 2006 fiscal year. Management also will provide an update on the Company.

The call may be accessed live by dialing 913-981-4900. No passcode is required. Playback of the call will be available from 7:30 p.m. on May 4, 2006, through 11:59 p.m. on May 10, 2006. To listen to the playback, please call 719-457-0820 and provide passcode 1727841.

Additionally, the call can be heard through the Investor Relations section of ImmunoGen's website, http://www.immunogen.com. Please connect to this website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Following the live webcast, an archived version of the call will be available on at the same location through May 10, 2006.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Three TAP compounds are in clinical testing -- huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633, which is in development by the sanofi-aventis Group. A fourth TAP compound, trastuzumab-DM1 in development by Genentech, now has an effective IND. Genentech, Centocor (a wholly-owned subsidiary of Johnson & Johnson), Biogen Idec, the sanofi-aventis Group, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim, and Amgen (formerly Abgenix) have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group.

CONTACT: ImmunoGen, Inc.
Carol Hausner, 617-995-2500
info@immunogen.com

SOURCE: ImmunoGen, Inc.